1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Presence Of Patient Experience Data Table In FDA Drug Review Summaries ‘Inconsistent’

 
• By Cathy Kelly

RTI Health Solutions researchers assessed US FDA review documents over past two years to gauge use of a tool meant to facilitate agency disclosures about what patient experience information it considered.

Medical technology, telemedicine, e-health, medical online, electronics health record system concept. male doctor working on digital tablet computer with web icons technology on virtual screen.
A Patient Experience Data Checklist For Review Summaries

The US Food and Drug Administration is making progress with its implementation of a patient experience data summary section in new drug review documents but there are still inconsistencies, RTI Health Solutions' Ari Gnanasakthy reported at ISPOR's recent annual meeting.

The patient experience data table outlines whether and what patient experience data had been submitted with an application. The FDA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Former CBER Director Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

More from Agency Leadership

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.